



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 



Anti-CD154 [IDEC-131 (Toralizumab)] Standard Size, 200 µg, Ab01678-3.3  
[View online](#)

## **Anti-CD154 [IDEC-131 (Toralizumab)] Standard Size Ab01678-3.3**

This antibody was created using our proprietary Fc Silent™ engineered Fc domain containing key point mutations that abrogate binding to Fc gamma receptors.

This chimeric mouse antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques.

**Isotype and Format:** Mouse IgG2b, Fc Silent™, Kappa

**Clone Number:** IDEC-131 (Toralizumab)

**Alternative Name(s) of Target:** CD40L; gp39; TRAP; Tumor necrosis factor ligand superfamily member 5; TNFSF5; T-cell antigen Gp39; TNF-related activation protein; TNF-related activation protein

**UniProt Accession Number of Target Protein:** P29965

**Published Application(s):**

**Published Species Reactivity:** Human

**Immunogen:** The original monoclonal antibody was generated by immunization with a soluble fusion protein of human gp39 (gp39-CD8).

**Specificity:** This antibody is a non agonistic antibody specific for human CD40 ligand.

**Application Notes:** This antibody binds CD154 with a binding affinity of  $K_d = 5.6$  nM for the originally characterized antibody (Brams et al., 2001)/ Phase I clinical trials of the antibody in patients with systemic lupus erythematoses revealed that a single intravenous infusion at doses of 0.05-15.0 mg/kg is safe and well tolerated in patients. (Davis et al., 2001). Although, no further development for this indication has been reported since the disclosure of disappointing phase II results in April 2000. In January 2001, phase II trials in psoriasis and idiopathic thrombocytopenic purpura (ITP) were initiated. By January 2002, a phase II trial in Crohn's disease was also ongoing. (Dumont FJ, 2002) Ab IDEC-131 was tested alone and in combination with rapamycin and DST for its ability to inhibit rhesus MLRs and it was seen that therapy with IDEC-131, rapamycin, and DST induced long-term allograft survival without intermittent acute rejection. (He Xu et al., 2003) IDEC-131 was also used in a comparative study using 3 monoclonal antibodies  $\alpha$ CD40 (2C10R4) and  $\alpha$ CD154 (5C8H1 and IDEC-131 to check CD40/CD154 T cell costimulation pathway in a non-human primate cardiac allotransplant model (O'Neill et al., 2017) Other suitable use in ELISA, FC, IF, IP.

**Antibody First Published in:** Patent US6001358 [PMID:](#)

**Note on publication:**

## Product Form

**Size:** 200  $\mu$ g Purified antibody.

**Purification:** Protein A affinity purified

**Supplied In:** PBS with 0.02% Proclin 300.

**Storage Recommendation:** Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.

**Concentration:** 1 mg/ml.

Important note - This product is for research use only. It is not intended for use in therapeutic or diagnostic procedures for humans or animals.